A novel method to detect hPG₈₀ (human circulating progastrin) in the blood

Area of Science:

• Biochemistry
• Oncology
• Clinical Chemistry

Background:

• Human circulating progastrin (hPG80) is produced by cancer cells and detected in patient blood.
• hPG80 detection suggests potential utility for early cancer detection across various origins.
• Accurate quantification of hPG80 is crucial for its clinical application.

Purpose of the Study:

• To develop and validate a reliable assay for measuring hPG80 in blood.
• To establish the analytical performance characteristics of the DxPG80 test.
• To assess the suitability of the DxPG80 test for cancer detection applications.

Main Methods:

• Development of a sandwich Enzyme-Linked Immunosorbent Assay (ELISA) named DxPG80.
• Evaluation of analytical performances including specificity, linearity, trueness, accuracy, and variability.
• Determination of the limit of detection (LoD) and limit of quantification (LoQ).

Main Results:

• The DxPG80 test demonstrated high specificity for hPG80, with no cross-reactivity or interference.
• The assay showed linearity between 0 and 50 pM hPG80.
• Trueness, accuracy, and variability were within the recommended 20% relative error, with LoD at 1 pM and LoQ at 3.3 pM.

Conclusions:

• The DxPG80 test exhibits strong analytical performance for quantifying hPG80 in blood samples.
• The assay's characteristics support its potential use as a biomarker for cancer detection.
• Further clinical validation is warranted to confirm hPG80's role in cancer diagnostics.